Diabetes is a growing global health crisis, affecting over 530 million adults. A central challenge in managing the disease is appetite dysregulation, which often leads to overeating, weight gain, and poor glycemic control. In recent years, gut hormones have emerged as key players in the interplay between food intake, energy balance, and metabolism. Understanding how these hormones function and how they become disrupted in diabetes is opening new avenues for treatment. This article explores the critical relationship between gut hormones and appetite regulation in diabetes, highlighting the latest research findings and their implications for therapy.

Overview of Gut Hormones in Appetite Regulation

The gastrointestinal tract produces a range of signaling molecules that influence hunger, satiety, and metabolic processes. These gut hormones act on the brain and peripheral tissues to coordinate the body’s response to food. Among the most studied are ghrelin, peptide YY (PYY), glucagon-like peptide-1 (GLP-1), and cholecystokinin (CCK). Each hormone plays a distinct role, and their combined activity shapes the appetitive state before, during, and after meals.

Ghrelin: The Hunger Hormone

Ghrelin is primarily produced by P/D1 cells in the stomach fundus and is often referred to as the “hunger hormone.” Its levels rise before meals and fall after eating, signaling the brain to stimulate appetite and promote food intake. Ghrelin acts on the hypothalamus, specifically the arcuate nucleus, to activate orexigenic neurons that release neuropeptide Y (NPY) and agouti-related peptide (AgRP). In people with diabetes, ghrelin regulation is frequently altered. Studies show that individuals with type 2 diabetes (T2D) often have lower fasting ghrelin levels compared with healthy controls, which paradoxically may contribute to a muted satiety response after meals. This altered ghrelin dynamic can disrupt normal hunger cues, making it harder for patients to control their caloric intake.

Peptide YY (PYY): Promoting Satiety

Peptide YY is secreted by L-cells in the distal ileum and colon in proportion to caloric intake. There are two major forms: PYY(1-36) and PYY(3-36). PYY(3-36) is the more active form and reduces appetite by binding to Y2 receptors in the hypothalamus. Postprandial release of PYY helps terminate eating and prolongs the feeling of fullness. In T2D, fasting and meal-stimulated PYY levels are often reduced, which contributes to accelerated gastric emptying and excessive hunger. Research indicates that lower PYY levels correlate with higher body mass index (BMI) and poorer glucose control, underscoring the hormone’s importance in diabetes management. Boosting PYY signaling, either through lifestyle interventions or pharmacological means, represents a promising strategy.

GLP-1: Beyond Insulin Secretion

Glucagon-like peptide-1 is produced by intestinal L-cells and is released in response to nutrient ingestion. Its well-known role is to enhance glucose-dependent insulin secretion from pancreatic beta cells. However, GLP-1 also exerts powerful effects on appetite regulation. It slows gastric emptying, stimulates afferent vagal nerves to signal satiety to the brain, and acts directly on GLP-1 receptors in the hypothalamus. In T2D, endogenous GLP-1 secretion is often impaired, which contributes to both hyperglycemia and increased appetite. The development of GLP-1 receptor agonists (GLP-1RAs) such as liraglutide and semaglutide has transformed diabetes treatment by simultaneously improving glycemic control and promoting weight loss. These agents mimic the satiety-enhancing and insulinotropic effects of native GLP-1, often leading to 10–15% reduction in body weight in clinical trials.

Cholecystokinin (CCK) and Other Hormones

CCK is released from I-cells in the duodenum and jejunum in response to fats and proteins. It stimulates gallbladder contraction, pancreatic enzyme secretion, and induces short-term satiety by activating CCK-A receptors on vagal afferent neurons. While less widely discussed in the diabetes literature, CCK may also modulate insulin secretion and glucose tolerance. Additional hormones like oxyntomodulin (OXM), glucose-dependent insulinotropic polypeptide (GIP), and amylin contribute to the complex hormonal milieu that governs appetite and metabolism. Each interacts with the others to fine-tune energy balance, and their collective dysregulation in diabetes creates a challenging environment for weight management.

Mechanisms of Gut Hormone Signaling

The communication between the gut and the brain is mediated through multiple pathways. After a meal, nutrients trigger the release of gut hormones, which can act locally on enteric nerves, enter the bloodstream, and cross the blood-brain barrier at circumventricular organs. The vagus nerve serves as a rapid relay, transmitting signals from the gut to the nucleus tractus solitarius (NTS) in the brainstem. From there, information is integrated in the hypothalamus, particularly the arcuate nucleus and paraventricular nucleus, to adjust feeding behavior and energy expenditure. This gut-brain axis is finely tuned; any disruption can lead to hyperphagia (excessive hunger) or hypophagia (loss of appetite).

The arcuate nucleus contains two main populations of neurons: one expressing pro-opiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART), which promote satiety; and another expressing NPY and AgRP, which stimulate hunger. Gut hormones like ghrelin activate NPY/AgRP neurons, while PYY, GLP-1, and CCK activate POMC/CART neurons. This reciprocal regulation is essential for maintaining energy homeostasis.

In diabetes, these signaling pathways are often compromised. For example, chronic hyperglycemia can impair vagal nerve function, reducing the brain's ability to respond to satiety signals. Additionally, insulin resistance in the hypothalamus blunts the anorectic effects of leptin and GLP-1, further promoting overeating. Recent research using functional MRI has shown that individuals with T2D have altered brain responses to visual food cues and gut hormone infusions, suggesting that central processing of appetite signals is fundamentally changed.

Dysregulation in Diabetes

The progression of diabetes—whether type 1 or type 2—is accompanied by significant alterations in the gut hormone profile. These changes not only affect appetite but also contribute to the metabolic deterioration characteristic of the disease.

Type 2 Diabetes and Satiety Hormone Deficits

In T2D, the most consistent finding is reduced postprandial secretion of the satiety hormones GLP-1, PYY, and oxyntomodulin. This deficiency leads to inadequate suppression of hunger after meals, promoting a cycle of overeating and weight gain that exacerbates insulin resistance. Some studies report that the magnitude of GLP-1 reduction correlates with the degree of beta-cell dysfunction, suggesting that impaired incretin signaling is an early feature of T2D. At the same time, fasting ghrelin levels are often low, which might appear contradictory. However, the loss of the normal ghrelin dipping response after meals means that the hunger signal is not properly shut off, contributing to sustained appetite.

Type 1 Diabetes: Altered Ghrelin and GLP-1

In type 1 diabetes (T1D), the autoimmune destruction of beta cells eliminates endogenous insulin production. This leads to a different hormonal landscape. Ghrelin levels tend to be elevated in T1D, possibly due to insulin deficiency, which can stimulate strong hunger signals. GLP-1 secretion, on the other hand, is often preserved or even increased in some studies, but its efficacy is limited because of the lack of beta cells to respond to its insulinotropic action. However, GLP-1RAs have still shown benefits in T1D by reducing postprandial glucagon, slowing gastric emptying, and decreasing appetite, leading to weight loss and improved glycemic variability. The appetite-regulating effects of PYY and CCK in T1D remain less studied, but emerging evidence suggests they also become dysregulated, potentially contributing to the eating disorders and body weight issues common in this population.

Research Findings and Clinical Evidence

A growing body of clinical research has quantified the impact of gut hormone modulation in diabetes. One landmark trial, the SCALE (Satiety and Clinical Adiposity – Liraglutide Evidence) program, demonstrated that the GLP-1 receptor agonist liraglutide, at a dose of 3.0 mg daily, reduced body weight by an average of 8–10% compared with placebo in people with T2D and obesity. Participants reported significant reductions in hunger and cravings, confirming the drug’s appetite-suppressing effects. Similarly, the STEP (Semaglutide Treatment Effect in People with Obesity) trials with semaglutide 2.4 mg showed weight reductions of up to 15% and improvements in glycemic control, largely mediated by enhanced satiety and delayed gastric emptying.

Outside of pharmacological interventions, bariatric surgery (particularly Roux-en-Y gastric bypass) dramatically alters gut hormone secretion. Post-surgery, patients experience a sharp rise in GLP-1 and PYY levels, along with a decrease in ghrelin, leading to sustained weight loss and remission of T2D in many cases. This surgical model provides strong evidence that gut hormones are not just biomarkers but causal drivers of appetite regulation and metabolic improvement. Researchers are now working to replicate these hormonal changes with less invasive pharmacotherapies, including dual and triple agonists targeting GLP-1, GIP, and glucagon receptors. Early-phase clinical trials of triagonists such as retatrutide have shown unprecedented weight loss of 24% or more, with a corresponding improvement in glucose metabolism.

Additionally, a 2021 meta-analysis published in Diabetes Care reviewed over 30 randomized controlled trials and concluded that GLP-1RA therapy significantly reduces ad libitum energy intake by 20–30% compared with placebo, while also lowering HbA1c by 1.0–1.5 percentage points. The effects are dose-dependent and maintained for up to 2 years with continued treatment. These findings collectively reinforce the central role of gut hormones in appetite regulation and support their therapeutic targeting in diabetes.

Therapeutic Implications

The understanding of gut hormone biology has directly led to new classes of diabetes medications. GLP-1 receptor agonists are now first-line therapies for many patients with T2D, especially those with obesity or high cardiovascular risk. Liraglutide (Victoza/Saxenda) and semaglutide (Ozempic/Wegovy) have become blockbuster drugs, not only for glucose control but for their robust weight loss effects, which are driven by appetite suppression. The recent approval of tirzepatide (Mounjaro), a dual GIP/GLP-1 receptor agonist, has further expanded the armamentarium, with clinical data showing superior HbA1c reduction and weight loss compared with selective GLP-1RAs. Tirzepatide’s additional activity on GIP receptors may enhance satiety through distinct mechanisms, such as increasing energy expenditure and improving lipid metabolism.

For patients with T1D, the use of GLP-1RAs is still off-label in many regions, but an increasing number of clinicians prescribe them to help manage weight and reduce insulin doses. Pramlintide (Symlin), an analog of amylin, has been available for years as an adjunct to insulin in both T1D and T2D and works partly by slowing gastric emptying and promoting satiety. However, its use is limited by dosing complexity and side effects. Future therapies may include oral gut hormone-based medications (oral semaglutide is already approved) and longer-acting formulations that improve convenience and adherence.

Personalized medicine is also on the horizon. Genetic variations in GLP-1 receptor or PYY genes may predict individual responses to appetite-suppressing therapies. Tailoring treatment based on a patient’s gut hormone profile could maximize efficacy and minimize adverse effects. For instance, individuals with inherently low GLP-1 secretion might be ideal candidates for GLP-1RA therapy, while those with elevated ghrelin might benefit more from ghrelin receptor antagonists, which are currently in early development.

Future Research Directions

The relationship between gut hormones and appetite regulation in diabetes remains a vibrant field of investigation. Several key areas are poised for breakthroughs:

  • Microbiome-gut hormone axis: The gut microbiota produces metabolites such as short-chain fatty acids (SCFAs) that stimulate L-cell secretion of GLP-1 and PYY. Fecal microbiota transplantation and prebiotic interventions are being studied to enhance endogenous hormone release and improve appetite control in diabetes.
  • Brain imaging and behavior: Advanced fMRI and PET imaging are helping to map how gut hormone changes alter food reward processing and hedonic eating. Understanding why some patients continue to crave high-calorie foods despite elevated satiety hormones could lead to cognitive-behavioral or adjunctive therapies.
  • Long-term safety and durability: While GLP-1RAs are generally safe, concerns about pancreatitis, thyroid C-cell tumors, and gastrointestinal side effects persist. Ongoing post-marketing surveillance and trials with newer agonists will clarify the risk-benefit profiles.
  • Combination therapies: Combining gut hormone modulators with other agents—such as sodium-glucose cotransporter-2 (SGLT2) inhibitors or leptin analogs—may produce additive or synergistic effects on appetite and metabolism. Early studies of GLP-1/glucagon dual agonists have shown promise.
  • Pediatric and adolescent diabetes: Appetite dysregulation is especially problematic in young people with T1D and T2D. Clinical trials of GLP-1RAs in adolescents have already yielded positive results, but more research is needed to understand the optimal timing and dosing for this population.

In conclusion, the interplay between gut hormones and appetite regulation is a cornerstone of metabolic health. In diabetes, this system is commonly disrupted, contributing to weight gain, poor glycemic control, and diminished quality of life. However, recent research has not only elucidated these mechanisms but has also delivered powerful therapeutic tools that directly target the gut hormone axis. As our understanding deepens, the potential for even more effective, personalized interventions grows. The ongoing scientific effort promises to transform how we approach appetite management in diabetes, moving beyond simple caloric restriction toward precise hormonal modulation.

For further reading, consult the National Center for Biotechnology Information review on gut hormones and glucose metabolism, the FDA information page on GLP-1 receptor agonists, and the American Diabetes Association meta-analysis of GLP-1RA effects on appetite.